Coverage
-
June 08, 2023
Two convicted former executives of skin graft biotechnology company MiMedx have agreed to pay nearly $2 million to the U.S. Securities and Exchange Commission to resolve claims they played a role in orchestrating a "pervasive, long-running fraud" that saw the company strike backroom deals with distributors to misstate millions of dollars of revenue in its public filings.
3 other articles on this case.
View all »